OBJECTIVE： To analyze the clinical application and trend of antitumor drugs in 42 hospitals from Beijing， Shanghai and Chengdu， and to provide reference for rational drug use in clinic. METHODS： The utilization of antitumor drugs in 42 hospitals from Beijing， Shanghai and Chengdu during 2012-2016 was analyzed statistically in respects of consumption sum， DDDs. RESULTS： The consumption sum of antitumor drugs in 3 cities， Beijing ranked the first； annual growth rate of Shanghai was the highest. In the list of consumption sum of antitumor drugs of 3 cities in 5 years， immunosuppressive agents as tacrolimus， mycophenolate mofetil were among top 10 antitumor drugs in the list of consumption sum. Top 1 antitumor drug in the list of consumption sum in Beijing， Shanghai and Chengdu were thymopentin， tacrolimus and thymalfasin， respectively. Among subtype of antitumor drugs， other antitumor drugs and adjuvant drugs in Beijing and Chengdu during 2012-2014 took up the first place in the list of consumption sum； the consumption sum of antimetabolite during 2015-2016 occupied the first place， and that of Beijing was higher than that of Chengdu. The cost of antimetabolite in Shanghai during 2012-2016 was the highest. The consumption sum of other antitumor drugs and adjuvant drugs were the highest in 3 cities during 2012-2014； that of antimetabolite was the highest during 2015-2016. Among related drugs， immune enhancer， immunosuppressive agents and analgesics ranked the top in the list of consumption sum. Among top 10 antitumor drugs in the list of DDDs， most were antineoplastic medicine， and only cyclophosphamide among alkylating agents entered the ranking. CONCLUSIONS： The growing trend of antitumor concumption sum is stable. Antimetabolite， hormones and plant-derived antitumor are becoming larger. Molecular targeted therapies have a good prospect for application.